DCVAC/PCa is an active cellular immunotherapy designed to initiate an immune response against prostate cancer.
To evaluate the efficacy and safety of DCVAC/PCa plus chemotherapy followed by DCVAC/PCa maintenance treatment in patients with metastatic castration-resistant prostate cancer (mCRPC).